244 related articles for article (PubMed ID: 12694391)
1. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity.
Saura J; Parés M; Bové J; Pezzi S; Alberch J; Marin C; Tolosa E; Martí MJ
J Neurochem; 2003 May; 85(3):651-61. PubMed ID: 12694391
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
3. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
4. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Carbone M; Duty S; Rattray M
BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
[TBL] [Abstract][Full Text] [Related]
5. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
6. Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine.
Rodrigues RW; Gomide VC; Chadi G
Int J Neurosci; 2001 Jul; 109(1-2):91-126. PubMed ID: 11699344
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Boshoff EL; Fletcher EJR; Duty S
Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the cellular distribution of bcl-2, bcl-x and bax in the adult rat substantia nigra following striatal 6-hydroxydopamine lesions.
Kramer BC; Mytilineou C
J Neurocytol; 2004 Mar; 33(2):213-23. PubMed ID: 15322379
[TBL] [Abstract][Full Text] [Related]
9. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
[TBL] [Abstract][Full Text] [Related]
10. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
11. Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat.
Martí MJ; Saura J; Burke RE; Jackson-Lewis V; Jiménez A; Bonastre M; Tolosa E
Brain Res; 2002 Dec; 958(1):185-91. PubMed ID: 12468044
[TBL] [Abstract][Full Text] [Related]
12. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
Fletcher EJR; Moon LDF; Duty S
BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
[TBL] [Abstract][Full Text] [Related]
13. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
Gomide V; Bibancos T; Chadi G
Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
[TBL] [Abstract][Full Text] [Related]
14. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism.
Gonzalez-Aparicio R; Blanco E; Serrano A; Pavon FJ; Parsons LH; Maldonado R; Robledo P; Fernandez-Espejo E; de Fonseca FR
Int J Neuropsychopharmacol; 2014 Mar; 17(3):455-68. PubMed ID: 24169105
[TBL] [Abstract][Full Text] [Related]
15. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease.
Garbayo E; Ansorena E; Lanciego JL; Blanco-Prieto MJ; Aymerich MS
Mov Disord; 2011 Aug; 26(10):1943-7. PubMed ID: 21661048
[TBL] [Abstract][Full Text] [Related]
16. Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.
Anastasía A; Torre L; de Erausquin GA; Mascó DH
J Neurochem; 2009 May; 109(3):755-65. PubMed ID: 19245661
[TBL] [Abstract][Full Text] [Related]
17. DJ-1 protein protects dopaminergic neurons against 6-OHDA/MG-132-induced neurotoxicity in rats.
Sun SY; An CN; Pu XP
Brain Res Bull; 2012 Sep; 88(6):609-16. PubMed ID: 22664331
[TBL] [Abstract][Full Text] [Related]
18. Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats.
Inden M; Kitamura Y; Kondo J; Hayashi K; Yanagida T; Takata K; Tsuchiya D; Yanagisawa D; Nishimura K; Taniguchi T; Shimohama S; Sugimoto H; Akaike A
J Neurochem; 2005 Nov; 95(4):950-61. PubMed ID: 16135081
[TBL] [Abstract][Full Text] [Related]
19. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
20. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.
Cunningham LA; Su C
Exp Neurol; 2002 Apr; 174(2):230-42. PubMed ID: 11922664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
